Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using phosphoproteomics we showed that BRAF inhibition mediates a switch to an aggressive/metastatic melanoma phenotype that is driven by ligand-independent erythropoietin-producing hepatocellular receptor A2 (EphA2) signaling.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905349 | PMC |
| http://dx.doi.org/10.1080/23723556.2015.1008291 | DOI Listing |
Publication Analysis
Top Keywords
inhibition braf
4
braf braf+mek
4
braf+mek drives
4
drives metastatic
4
metastatic switch
4
switch melanoma
4
melanoma analyses
4
analyses group
4
group majority
4
majority melanoma
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!